Updated data showed the biotech's approach to the rare lung and liver condition helped restore functional protective proteins ...

Investors had reservations over data from Maze for a drug that could compete with a candidate from Vertex in a ...

Long-awaited results from Phase 1/2 studies lifted Sarepta’s stock and, according to the company, suggest potential for two ...

If consummated, the deal would hand Merck a treatment that could challenge Novartis’ fast-selling Scemblix. But the low ...

The fresh funding will help the biotech startup advance a candidate to treat a genetic disorder, “ATTR-CM,” that has become a ...

The prominent investor aims to merge its latest special purpose acquisition company with a Chinese biotech, according to a ...

Xpovio combined with Incyte’s Jakafi helped on one key measure but missed on other goal in a disorder that, by one analyst’s ...

Acquiring Ouro Medicines, which launched last year, hands Gilead an antibody designed to bind to BCMA and CD3, a pair of immune cell proteins that are popular targets for drugmakers.

Cohen says he looked at around two dozen companies since Acorda wound down. Oryon Cell Therapies, with its funding, data and ...

Company shares climbed by more than 20% on Phase 2 study results suggesting the therapy could provide sustained relief when ...

The partners said the shot produced “clinically meaningful” efficacy despite missing its main study objective, a finding they ...

Industry executives can share their views on the “national priority” program at a June meeting. Elsewhere, Sanofi licensed a ...